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Abstract: Aging is a complex multi-layered phenomenon. The study of aging in humans is based on
the use of biological material from hard-to-gather tissues and highly specific cohorts. The introduction
of cell reprogramming techniques posed promising features for medical practice and basic research.
Recently, a growing number of studies have been describing the generation of induced pluripotent
stem cells (iPSCs) from old or centenarian biologic material. Nonetheless, Reprogramming techniques
determine a profound remodelling on cell epigenetic architecture whose extent is still largely debated.
Given that cell epigenetic profile changes with age, the study of cell-fate manipulation approaches on
cells deriving from old donors or centenarians may provide new insights not only on regenerative
features and physiology of these cells, but also on reprogramming-associated and age-related
epigenetic derangement.
Keywords: aging; cell reprogramming; induced Pluripotent Stem Cells; DNA methylation
1. Introduction
Due to the increasing life expectancy of the population of industrialised countries and the
ever-growing increase in the need for hospitalisation and health care management for the elderly,
research in the field of aging has gained in the last few decades a particular relevance within the
scientific community.
Aging is complex phenomenon where genetic, epigenetic, stochastic, and environmental factors
intervene in determining a variably quick, progressive physiological decline [1]. Earliest studies on
aging and longevity relied on the use of animal models of increasing complexity (from yeast to mice) [2].
Aging studies on human relied on the analysis of large tissue repositories from numerous subjects at
different age or repositories of samples from follow up studies. The need for large cohorts of patients
at different age or for long-term follow-up studies, and the limited availability for certain tissues made
these studies particularly challenging.
The introduction of cell reprogramming techniques granted researchers access to a theoretically
unlimited source of hard-to-gather, genetically homogenous cell types and tissues. Cell reprogramming
is based on inducing the expression of immature state-specific transcription factors (OCT4, SOX2,
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KLF4, c-MYC, or original Yamanaka reprogramming factors (OSKM)) in adult somatic cells, thus
achieving cell fate conversion from a nullipotent, mature state to a pluripotent, embryonic-like one [3].
Early approaches were based on integrating vector-mediated delivery of reprogramming factors
(OSKM) that subsequently evolved through the years in order to grant generation of bona fide induced
pluripotent stem cells (iPSCs) devoid of any viral and virally inserted components [4–7].
Induced pluripotent stem cells revolutionized the field of cell-based disease modelling, including
age-related pathologic conditions. Indeed, iPSCs have been successfully applied in order to study
the onset of several age-related degenerative disorders, such as Alzheimer’s Disease [8], Parkinson
Disease (PD) [9,10], and Diabetes Mellitus [11], but also to monitor cellular physiology derangement
in accelerated-aging pathologies such as Hutchinson-Gilford progeria [12] and Werner Syndrome [13].
Age is intrinsically associated with cell fate and influences the outcome of cell-fate manipulating
procedure in two ways: it regulates the ability of the cells to be reprogrammed and it influences
the ability of reprogrammed cells to generate fully proficient tissues. Only a limited series of works
investigates how age influences reprogramming and how aging trajectories are affected following
reprogramming and differentiation.
In this review, we will summarize existing literature studying the effect of age on cell reprogramming.
In addition, we will examine how hallmarks of age are modified by extensive cell fate manipulation with
major attention given to DNA methylation (DNAm). Finally, we will get further insights on how age
trajectories are altered following reprogramming and differentiation.
2. Effects of Donor’s Age on Cell Reprogramming
Induced pluripotent stem cells have been generated from a large set of different tissues [5]
deriving from subjects of different age [14]. Nevertheless, while iPSC-relevant literature overflows with
evidence of reprogramming from young-derived cells, the use of elderly-derived tissues seems largely
limited. Early experiments that were performed on cells deriving from young and old mice allowed
for the derivation of pluripotent stem cells, confirming that reprogramming could affect cells at any
age. Using Yamanaka’s factor and a retroviral vector, Kim et al. [15] generated iPSC from 12-month
old mice dermal fibroblasts and bone-marrow hematopoietic progenitors at an efficiency (0.02%)
five-fold lower when compared to juvenile mice (0.1%). These cells expressed pluripotency-associated
markers and were able to differentiate both in vivo and in vitro into all three germ layers, as well as
generate CD11b, CD115-positive myeloid cells. Afterwards, Wang [16] successfully reprogrammed
1.5-month (1.5 m), 6-month (6 m), and 14-month (14 m) old mice fibroblasts into iPSC. Reprogramming
of 1.5 m and 6 m old mice fibroblasts generated six times more iPSC colonies than 14 m old ones [16].
In addition, Cheng et al. [17] showed that bone marrow cells deriving from two-month old mice
could be reprogrammed at a fivefold lower efficiency and twofold slower rate when compared to
23-month old ones.
These studies highlighted a generally lower reprogramming efficiency for slow-replicating,
elderly-derived cells when compared to fast-replicating, young-derived ones.
Indeed, the age of cell donor is one of the various factors that have been correlated alongside
transfection approach and tissue of origin to reprogramming efficiency of both mouse and human
somatic tissues.
Reprogramming of elderly-derived dermal fibroblasts has been proven to be less efficient when
compared to young or neonatal ones. Trokovic et al. [18] observed a negative correlation (r = −0.8916;
p value = 0.0002) between donor’s age and reprogramming efficiency of dermal fibroblasts transfected
with a retroviral OSKM vector. The reported reprogramming efficiencies varied from 0.06% in newborn
fibroblasts to 0 in 83-years-old ones. As a further notice, the authors highlight a negative association
between reprogramming efficiency and replicative passages thus supporting previously reported
evidence suggesting the role of p16/p21-dependent senescence response in determining refractoriness
of elderly deriving cells to cell-fate manipulations [19].
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Despite lower efficiency when compared to young subjects, reprogramming of elderly-derived
human fibroblasts into bona fide iPSCs is feasible and has been achieved by multiple research
groups, as indicated in Table 1. In one of the earliest attempts, Boulting et al. [20] used a retroviral
OCT4-SOX2-KLF4 (OSK) vector to transduce human fibroblasts gathered from individuals up to
82 years old. iPSC lines generated from both young and old subjects showed pluripotent markers
expression and displayed proficiency to differentiate in vitro and in vivo into all three germ layers.
Table 1. List of works achieving reprogramming of old- or centenarian-derived tissues.
Reference Species Age of Donor Tissue Vector Factors Efficiency
Kim et al. [15] Mouse Juvenile and 12 m DF; BM Retroviral OSKM 5 times higher in juvenilethan 12 m old
Cheng et al. [17] Mouse 2 m and 23 m BM Retroviral OSKM 5 times higher and 2 timesfaster in 2 m than 23 m old
Wang et al. [16] Mouse 1.5 m; 6 mand 14 m DF Retroviral OSKM
6 times higher in 1.5 m and
6 m than 14 m old
Miller et al. [21] Human 11 y.o.; 31–55 y.o.;71–96 y.o. DF Sendai OSKM Not assessed
Lapasset et al. [22] Human 92 y.o.; 94 y.o.;96 y.o.; 101 y.o. DF Lentiviral OSKMNL Not assessed
Yagi et al. [23] Human 106 y.o. DF Retroviral OSKM Not assessed
Wen et al. [24] Human 47 y.o. and 78 y.o. DF Lentiviral OSKM
1.3 times more fully
reprogrammed lines from
47 y.o. compared to 78 y.o.
Boulting et al. [20] Human 29–82 y.o. DF Retroviral OSK Not assessed
Frobel et al. [25] Human 56 y.o.; 63 y.o.;74 y.o. MSC Retroviral OSKM Not assessed
Ohmine et al. [26] Human 56–78 y.o. Keratinocytes Lentiviral OSKM Not assessed
Trokovic et al. [18] Human 0-83 y.o. DF Retroviral OSKM
Negative correlation
between donor’s age and
reprogramming efficiency
(r = −0.89; p value = 0.0002)
Lo Sardo et al. [14] Human 20–100 y.o. PBMCs Plasmid +Electroporation OSKL
No differences in
reprogramming efficiency
were noticed with
increasing age
Age is reported either in months (m) or years (y.o.); DF: dermal fibroblasts; BM: bone marrow cells;
MSC: mesenchymal stem cells; PBMCs: Periferal Blood Mononuclear Cells; O: OCT4; S: SOX2; K: KLF4; M: c-MYC;
N: NANOG; L: LIN28.
Reprogramming from elderly-derived tissues was subsequently achieved using different
approaches. In 2012, Ohmine [26] reprogrammed keratinocytes from elderly (78 y.o.) Diabetes Mellitus
patients into pluripotent stem cells through a lentivirally-delivered OSKM-vector. Furthermore,
Wen [24] used a retroviral OSKM-vector to reprogram mucosal fibroblast from a 78 y.o. and 47 y.o.
women with pelvic floor disorders. Similarly, Frobel [25] achieved successful iPSC reprogramming
from 74 y.o. dermal fibroblasts by retrovirally-delivering the same set reprogramming factors.
The growing evidence supporting elderly-derived reprogramming feasibility led scientists to
start taking into consideration extreme aging phenotypes. In this frame, centenarian biological
material started to be considered for reprogramming. Centenarian subjects are unique tools in
the study of aging and longevity. Centenarians are, by definition, subjects who largely postponed
any major health-threatening, age-related disease. For this characteristic alone, centenarians are
considered extremely informative subjects since are the living representative for a healthy, disease-free,
aging process [27]. In 2011, Lapasset et al. [22] achieved reprogramming of mitotically inactive cells
and fibroblasts deriving from a 101 y.o. subject using a lentiviral vector containing LIN28; as well
as OCT3/4, SOX2, and c-MYC. Introduction of LIN28, which acts by preventing activation of cell
maturation and differentiation pathways, as well as NANOG, one of pluripotency master regulators,
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alongside canonical reprogramming factors was a necessary modification in order to grant generation
of iPSC lines from senescent and centenarian-derived dermal fibroblasts.
Centenarian-derived cell reprogramming has been replicated only recently. In fact, Yagi et al. [23]
managed to achieve full reprogramming of dermal fibroblasts deriving from two subjects, respectively,
106 y.o. and 109 y.o. Yagi used an updated version of Lapasset’s reprogramming method relying on
retroviral vector carrying the OSKM. The lack of LIN28 indicates that centenarian fibroblasts do not
require transcriptional boosting in order to be reprogrammed other than c-MYC, thus reducing the
risk of artefact development.
Further advances in reprogramming methodologies allowed for the generation of iPSC from
different centenarian tissue types. One example is represented by the work by Lo Sardo [14] and
colleagues who reprogrammed PBMC (Periferal Blood Mononuclear Cells) deriving from subjects
ranging from 20 to 100 y.o. using a plasmid-based episomal vector delivering OCT4-SOX2-KLF4-
cMYC-LIN28 (OSKML) reprogramming factors. Interestingly, in this case, reprogramming efficiency
has not been observed to change with chronological age.
Understanding the driving cause for longevity-associated phenotype is difficult and requires,
as previously mentioned, rather unique and highly relevant cohorts. In these regards, iPSCs generated
from centenarian biological material may configure as a possible model for the study of aging in
hard-to-gather tissue types.
It is evident though that in order to assess the reliability of iPSC models for the study of aging
and age-related conditions, it is first necessary to understand how age-related mechanisms are affected
by reprogramming.
3. Epigenetic Remodelling during Reprogramming and Differentiation
Cell reprogramming, have proven that processes involved in determination of cell fate and
development are regulated by factors are amenable of external manipulation. Cell reprogramming
influences cell fate on multiple levels. It does not promote only morphological mesenchymal-to-
epithelial transition, but it also deeply affects cell biochemical, transcriptional, and epigenetic landscape.
Existing evidence indicates reprogramming techniques exert a strong driving effect on several
standard age-associated markers such as telomere length [28]; DNA methylation [29,30]; histone
modifications [31]; expression of pro-inflammatory factors [32]; and, cell-cycle arrest [33].
Indeed, it has been shown that iPSC re-express telomerase and possess elongated telomeres [34];
present altered histone modification landscape as well as altered DNAm [35]; lack senescence-
associated gene expression [24,26]; and, possess mitochondria with increased energetic output and
reactive oxygen species (ROS) resistance [36].
Among all of the epigenetics mechanisms, DNAm is the one that in both human and mice [37]
showed the best performance as a biomarker of chronological age and in many cases with features of
biological age such as age-related diseases and mortality among others. The DNA methylation has
played an active role in many functions and processes cellular and tissue differentiation, development,
as well as cancerogenic transformation. Whether or not the age-related DNAm changes that occur with
age play in the onset of age-related physiological decline, and thus, more broadly, in the aetiology of
age-related diseases are still to be understood.
Cell reprogramming exerts a profound remodelling of DNAm profiles. All the somatic adult cells
lines possess a specific DNAm landscape that acts as an epigenetic fingerprint being indicative for their
type, age, and fate. Most (but not all) of these tissue-specific DNAm signatures are altered to favour
the establishment of an human embryonic stem cell-like (hESC) DNAm landscapes (Table 2) [38–42].
Despite this profound DNAm remodelling towards hESC state, cell reprogramming is not
able to fully reproduce human hESC DNAm landscape. Whole-genome bisulphite sequencing of
Yamanaka factor-derived iPSC, nuclear transfer (NT)-derived stem cells (SCs) with in vitro-fecundation
(IVF)-derived hESCs showed that iPSCs carried threefold more aberrant CpG and tenfold more aberrant
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non-CpG methylation when compared to NT hESCs [40]. In addition, iPSCs were reported to harbour
more aberrantly methylated sites at imprinted regions than NT and IVF SCs.
Table 2. Studies reporting DNA methylatation (DNAm) changes upon reprogramming.
Reference Species Tissues TransfectionVector
Reprogramming
Factors
Methylation Analysis
Technique
Ma et al. [40] Human FF Sendai virus OSKM
Infinium
HumanMethylation450
Illumina
Lister et al. [39] Human ADS Retrovirus OSKM Methyl-C Seq
Nishino et al. [42] Human FLF; AM; E;PDE; MB Retrovirus OSKM
Infinium
HumanMethylation27
Illumina
Planello et al. [41] Human FF Retrovirus OSKM/OSKL
Infinium
HumanMethylation450
Illumina
He et al. [38] Human FF; AF
Lentivirus OSKM
Infinium
HumanMethylation450
IlluminaEpisomal OSKMNL
Frobel et al. [25] HUMAN BM-MSC Retrovirus OSKM
Infinium
HumanMethylation450
Illumina
Shao et al. [43] Human MSC Retrovirus OSKM
Infinium
HumanMethylation450
Illumina
Lo Sardo et al. [14] HUMAN PBMCs eD_Plasmid OSKL
Infinium
HumanMethylation450
Illumina
GSC: Germline Stem Cells; FF: fetal fibroblasts; ADS: Adipose tissue-derived Stem Cells; FLF: Fetal Lung Fibroblasts;
AM: Amniotic Fluid Cells; E: Endometrium; PDE: Placenta-Derived Epithelium; MB: Menstrual Blood Cells;
BM-MSC: Bone Marrow Mesenchymal Stem Cells. eD_Plasmid: electroporated DNA plasmid.
It is evident that iPSCs present an altered epigenetic set-up, at least in terms of DNAm profiling
when compared to hESCs. To date, there are no data capable of explaining such differences, and most
importantly the possible effects that these different epigenetic profiles could exert in the downstream
regulations [44]. Moreover, no data is available to understand whether these differences in terms of
DNAm are reproducible and correlated with the age of the source cells.
Generally, methylation aberrations between reprogrammed cells and hESCs are classified into
two main categories: de novo and inherited or memory (Figure 1). The former refers to DNA regions
whose methylation levels are significantly different in iPSCs from both parental somatic cell line and
hESCs and are specific for each newly-established-iPSC line.
The latter refers to those DNA regions whose methylation levels are similar between iPSC and
somatic parental cell and different to hESC one [15,45]. Interestingly, memory DNAm aberrations have
been found to provide diagnostic information regarding the cell type [45] and age [14] of the source
cells used for reprogramming.
Amplitude of DNAm aberrations is highly inconsistent among different studies. For instance,
Lister et al. [39] showed that the vast majority of the differentially methylated regions identified
resulted hypomethylated when compared to hESCs [39]; while, Nishino et al. [42] showed that more
than 70% of the aberrantly methylated sites were hypermethylated in iPSC as compared to hESCs.
DNAm aberrations can also occur in genomic imprinted loci [46]. Similar to the above-mentioned
cases, DNAm aberrations at imprinted regions appear to be stochastic. Nevertheless, in a study from
Bar et al. [47] it was highlighted a specific dynamic of DNAm aberrations occurring at genomic
imprinted loci. In details, in this study it was observed that maternally imprinted loci tend to
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hypomethylation, on the contrary the paternally ones tend to a hypermethylated state. To date,
this is the only study that reported such DNAm dynamics and also in this case the aging covariate was
not assessed.
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by Lister et al. [39], average DNA methylation (DNAm) values of iPSCs r embles those of embry nic
st cell-like (hESCs). An extremely limi ed p rcentage of the sequ nced DNA subjected to odium
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Establishment of iPSC aberrant methylation profiles is subject to several variables. Among these,
the use of different reprogramming procedures. In fact, comparison of DNAm profiles of iPSCs generated
through Yamanaka or Thomson factors (OSKL)) revealed that the majority of aberrantly methylated
CpG sites in iPSCs were shared with the parental cell type. Strikingly, reprogramming-method specific
DNAm aberrations were identified. In particular, OSKM reprogramming was associated with aberrant
hypermethylation; OSKL reprogramming was associated with aberrant hypomethylation [41].
Aberrantly methylated region profiles are not stable and have been found to vary over cell
passaging and differentiation. In particular, both inherited and de novo CG-DMRs tend to decrease in
amplitude and quantity throughout passaging, ultimately resulting in a partial overlap between iPSC
and hESC methylomes [42].
Changes in DNAm profile over culturing suggest DNAm establishing mechanisms are active in
reprogrammed iPSC cells, thus allowing for further methylome re-shaping and re-differentiation into
somatic fate. According to existing literature, differentiation is associated with general reshaping of cell
methylome, resulting in hypermethylation of pluripotency-associated regions and hypomethylation
of lineage definition-associated ones [48,49]. Differentiation of iPSC into mesenchymal stem cells
confirmed the gradual loss of hypermethylation at tissue-specification sites (i.e., NTE5 and ENG)
and progressive hypermethylation at pluripotency gene-associated promoter (i.e., NANOG; OCT4).
Nevertheless, the methylome of differentiating iPSC never reached that of somatic adult mesenchymal
stem cells (MSCs) even after extensive cell differentiation [25]. Similarly, another study highlighted the
fact that DNAm profiles iPSC-derived despite being significantly separated from iPSC-DNAm ones,
never reached a similar DNAm profile as parental adult fibroblasts [50]. In another approach, analysis
of differentially methylated regions in a model of iPSC-derived dopaminergic neurons revealed
that only 35% of neurons-specific differentially methylated regions differed significantly from the
undifferentiated state [10].
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Incomplete or partial epigenetic differentiation is therefore a commonly observed phenomenon
when considering iPSC-based in vitro models. It is not clear whether these differences are associated
with limitations in the DNA-methylation establishing machinery or if they are related to a detrimental
effect associated with the presence of reprogramming-associated DNAm abnormalities. The fact that
a growing body of evidence indicates that iPSC/hESC differentiation efficiency is associated with their
DNAm profile indicates that the second hypothesis might be more realistic [51–53].
4. Epigenetic Age Changes upon Cellular Reprogramming and Differentiation
DNAm patterns are altered with age in all the cell types with directional and stochastic changes.
This was observed in humans and mammalian preclinical models [30,54,55].
Overall, age-related DNAm alterations follow this general rule: an overall hypomethylation
in heterochromatic regions and a gene promoter-specific hypermethylation [56,57]. Of course,
these general observations are subjected to a myriad of variants when considering the different genomic
regions, cell types, and environmental conditions with a marked inter-individual variability [58,59].
Variation in the methylation profile of age-related sites is so robust that several researchers
developed tools to measure epigenetic aging. Among the most noticeable examples, Horvath
developed an epigenetic aging clock based on a series of 353 CpG sites included in the Infinium
HumanMethylation 450 Beadchip (Illumina, San Diego, CA, USA) that allows for accurate age
prediction in a large set of healthy heterogenous tissues (PBMCs; whole blood; occipital cortex; breast
tissue; buccal epithelium; colon; fat adipose tissue; heart; kidney; liver; muscle; saliva) and individual
cell types (CD4 T-cells; CD14 monocytes and immortalized B cells) [55,60]. Horvath’s epigenetic clock
has been applied to study epigenetic aging trajectories in age-related health-threatening condition
(including Alzheimer’s [61] and PD [62]) in Down Syndrome [63], tumour development [64,65], but also
in healthy long-living individuals [66]. In addition, other tools were designed for the assessment of
biological aging by analysing CpG methylation at whole genome (Infinium HumanMethylation27
Beadchip, Illumina) [54], or just by focusing on few CpG sites [67]. Among the latters, it is of particular
notice the case of the biomarker of biological age based on ELOVL2 CpG island. In fact, this biomarker
was not found to be highly correlated with chronological age in blood [68] and dermal fibroblasts [69],
but also to highlight association between biological age-acceleration and cancer development [64].
The use of epigenetic-age predicting tools for the study of iPSCs and iPSC-derived cells
highlighted a sort of resetting of the epigenetic age.
Frobel et al. [25] and Lo Sardo et al. [14] studied the reprogramming-associated changes to DNAm
age using, respectively, Weidner’s [67] and Horvath’s [55] epigenetic clocks. Both studies reported
that the predicted DNAm age of iPSCs deriving from tissues at different age reset from the donor’s
epigenetic age to zero. Interestingly, further characterisation of DNAm age dynamics, as provided by
Frobel et al. [25], indicated that by differentiating iPSCs back into their parental cell type DNAm age
did not increase and only minor changes could be observed upon extensive culturing.
It is worth mentioning that at the moment it is not possible to assess whether the changes in the
methylation that is analysed for estimating the biological age produce any relevant biological effect.
Accordingly, to date those clocks can be considered just biomarkers. Therefore, any changes that can be
observed in any model system cannot be linked to a physiological recovery or acceleration of the aging
process. Accordingly, it is necessary to have dedicated studies to investigate whether the reset of the
methylation clock that occur in the iPSC generation protocol favour or not also a sort of rejuvenation
of the cells. To do it so, it is important that such studies carefully consider the age of the donor of the
source cell.
5. Impact of Reprogramming-Associated Alterations in the Study of Age-Related Diseases
The application of the analysis of DNAm pattern in iPSCs and their derivatives indicate that
while reprogramming is associated with a reversion of DNAm patterns to embryonic-like state,
the differentiation process does not lead to a full re-establishment of the cellular specific DNAm-profile.
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These results fit with what emerges from recent reports, indicating that tissues differentiated from
iPSCs do not present the same physiological and functional features of the target cells rather than they
are more similar to an immature version of their adult counterpart (Figure 2) [70,71].
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The generation of functionally immature tissues is a limitation for the study of age-related
phenomena or late-onset diseases, such as PD, whose specific phenotype is established over the course
of several decades. Indeed, PD-relevant iPSC-derived dopaminergic neurons showed only a marginal
increase in ROS susceptibility, disease-related gene expression, and α-Synuclein accumulation [72].
In order to gain a profile of disease-relevant characteristics, iPSCs-derived neurons required to undergo
in vitro aging through extensive culturing. Indeed, PD-relevant iPSC-derived neurons that were
cultured for an extended amount of time showed all disease-relevant characteristics that were lacking
or limited in the previous case (high sensitivity to ROS, α-Synuclein accumulation, mitochondria
morphological derangement) [72,73]. Mor recently, Miller et al. [21] pro osed a procedure that
enhances and accelerates age-related cellular mechanisms in vitro. In this study, for the first time it
was successfull app ied in vitro ce lular age-i ducing procedures based on the over-expression of
Progerin, a protein over expressed in premature aging syndrome [74] and aged fibroblasts [75].
By inducing acute over-expression of Progeri in young and old donor iPSC-derived
dopamin rgic neurons, Mille et al. [21] generated c llular model harbouring PD-relevant features
(mitochondrial deformation; increased ROS sens tivity; increased neurite degeneration). More recently,
Miller et l. published pr liminary data uggesting that i hibiting telomerase activity in iPSCs during
dopaminergic differentiation exhibited lower survivab lity, higher DNA damage, nd i creased ROS
production [76].
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6. Conclusions
Over the past few years, interest in the study of aging and age-related pathologies using cellular
models, including iPSC increased.
Obviously, cell fate manipulating techniques exert major remodelling over multiple cell
physiology-regulating mechanisms, including age-related ones. On the other hand, very little is known
regarding the capacity of these stem cells and their derivatives to follow “normal” age-associated
mechanics; thus, reliably reproducing the aging process for modelling studies.
In this review, we reported existing evidence linking iPSCs and aging studies in order to
understand how age-related mechanisms influence and are influenced by cell fate manipulating
techniques. We described how aging is associated with cell capacity to reprogram into pluripotent
state. Subsequently, we summarized existing literature reporting changes in age-related biochemical
and epigenetic markers, with particular attention to DNAm profile. Reprogramming-associated
alterations in cell physiology have been generally associated with the loss of age-related phenotype
and acquisition of an embryonic, undifferentiated state. In addition, whether reprogramming is largely
associated with reversion of adult-associated DNAm profile towards and embryonic-like state, several
methylation aberrations have been highlighted. De novo aberrations are independent to both parental
and embryonic DNAm profile, while memory aberrations are maintained from the specific-parental cell
DNAm landscape. Among the factors that are involved in the determination of parental cell-specific
DNAm profile is age. It is nowadays evident that DNAm changes with age. Age-associated DNAm
changes are robust within the population and contribute determining overall aging and health status.
Therefore, understanding how age-specific DNAm mechanics are reproduced in iPSC models is
fundamental, although largely neglected by existing literature.
The work we cited by Frobel et al. [25], is the first to apply a biological age-predicting tool for the
understanding of the DNAm age dynamics upon differentiation and in vitro aging of iPSC-derived
MSCs. The evidence they reported indicates that DNAm age is erased upon reprogramming and is not
re-established upon re-differentiation.
As already mentioned, existing data do not allow for drawing a clear association between
age-associated DNAm profiles and any age-related decline feature. Accordingly, it remains still unclear
whether erasure age-related DNAm signatures upon reprogramming is functionally associated with
physiological alteration of the overall age-related status of the cell. Additional concern can be drawn
considering the reliability of existing DNAm age predicting tools. Indeed, Horvath [55], Hannum [54],
and Weidner [67] epigenetic clocks are designed based on adult tissues differing tens of years of age.
Therefore, they might not be able to grasp DNAm age differences over iPSC-derived, embryo-like
differentiated cells and further validation has to be performed on this model.
It is evident that cell reprogramming and differentiation exert profound, stochastic changes whose
effect over cell-fate regulating approaches is unclear. Future studies are required to address whether
these changes are associated with a functional rejuvenation of the cells. Therefore, it will be critical
to thoroughly consider and assess the age of the donor of the source cells and determine whether at
different age corresponds also a different epigenetic and functional profile. Understanding this will
provide critical insight for considering the use of iPSC deriving from donors at different age for the
treatment and the modelling of major age-related health threatening disorders.
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